Last reviewed · How we verify
Medium-dosage SARS-CoV-2 vaccine
Medium-dosage SARS-CoV-2 vaccine is a inactivated viral vaccine Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved for Prevention of COVID-19 caused by SARS-CoV-2. Also known as: CoronaVac.
This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles.
This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles. Used for Prevention of COVID-19 caused by SARS-CoV-2.
At a glance
| Generic name | Medium-dosage SARS-CoV-2 vaccine |
|---|---|
| Also known as | CoronaVac |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains chemically inactivated whole SARS-CoV-2 virions that cannot replicate or cause disease. When administered, these inactivated particles trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize live virus upon exposure. The medium dosage formulation is designed to balance immunogenicity with tolerability.
Approved indications
- Prevention of COVID-19 caused by SARS-CoV-2
Common side effects
- Injection site pain or swelling
- Fatigue
- Myalgia
- Headache
- Fever
- Nausea
Key clinical trials
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (PHASE2)
- Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (PHASE1, PHASE2)
- A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers (PHASE1)
- Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California (PHASE4)
- Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents (PHASE1, PHASE2)
- Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Medium-dosage SARS-CoV-2 vaccine CI brief — competitive landscape report
- Medium-dosage SARS-CoV-2 vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI
Frequently asked questions about Medium-dosage SARS-CoV-2 vaccine
What is Medium-dosage SARS-CoV-2 vaccine?
How does Medium-dosage SARS-CoV-2 vaccine work?
What is Medium-dosage SARS-CoV-2 vaccine used for?
Who makes Medium-dosage SARS-CoV-2 vaccine?
Is Medium-dosage SARS-CoV-2 vaccine also known as anything else?
What drug class is Medium-dosage SARS-CoV-2 vaccine in?
What development phase is Medium-dosage SARS-CoV-2 vaccine in?
What are the side effects of Medium-dosage SARS-CoV-2 vaccine?
Related
- Drug class: All inactivated viral vaccine drugs
- Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of COVID-19 caused by SARS-CoV-2
- Also known as: CoronaVac
- Compare: Medium-dosage SARS-CoV-2 vaccine vs similar drugs
- Pricing: Medium-dosage SARS-CoV-2 vaccine cost, discount & access